Phage display, sequencing and developability assessment
The biopharmaceutical development process starts with target identiﬁcation and antibody discovery. Abzena oﬀers multiple approaches to antibody discovery and the isolation, development and selection of lead antibodies.
Abzena’s antibody discovery capability is based on the latest and most efficient hybridoma generation technologies coupled with high throughput robotic colony picking and liquid handling for highly efficient hybridoma screening. Read more >>>
Abzena’s platform for mRNA sequencing can determine the DNA and amino acid sequence of your antibody. Sequencing can be performed for IgG and IgM monoclonal antibodies produced by human, mouse and rat hybridoma cell lines. Read more >>>
Many physicochemical modiﬁcations can adversely impact on the molecular integrity of biologic molecules. Abzena can perform an in silico assessment to identify a number of potential sequence liabilities which, if not addressed, could lead to manufacturing challenges at a later stage. Read more >>>